Study ID (Protocol Number)
CA209-040
 
STUDY LOCATIONS*


 




*Not all study site locations may be listed - please check back soon for updated
information. For more information regarding other participating countries, please
visit clinicaltrials.gov.
  STUDY NAME
Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma)
STUDY OVERVIEW
The first part of the study is the Dose Escalation Phase designed to establish the safety of nivolumab at different dose levels for each of the three cohorts (uninfected HCC subjects, HCV-infected HCC subjects, and HBV-infected subjects). The second part of the study is the Expansion Phase designed to generate additional clinical data at specified doses for each of the 3 cohorts.
 

 
The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.
Find A Study